Finance

Enough consumers like the option, but most consumers don’t seem to love it as much as some retailers were hoping.

ACN earnings call for the period ending May 31, 2021.

Investors are breathing easier after the FDA’s response to a potential link between Moderna’s vaccine and heart inflammation issues.

Investors appear to be changing their minds about this rising tech star.

The rise of meme stocks continues, and analysts are now also chiming in.

Investors don’t like the company’s first-quarter update.

This seems to be a continuation of volatility resulting from fears of inflation.

A lot of promising debutantes have hit the market over the past year. Let’s go over some of the better ones that are now on sale.

Investors expecting Gilead Sciences to license Arcus Biosciences’ lead asset could be in for an unpleasant surprise.

The company’s promising Alzheimer’s disease drug won FDA Breakthrough Therapy designation.

Is the fintech giant’s price hike a show of strength or a fatal mistake?

Utility NRG Energy has an interesting business model, but things just haven’t gone very well in 2021. Does that create a buying opportunity?

The midstream sector is facing a material headwind as the world goes green. But that doesn’t mean that some players won’t thrive.

Looking for a military-industrial company to own? Then giant Lockheed Martin needs to be on your shortlist.

Cash flow is rebounding rapidly, and the West Coast airline expects to return to profitability next quarter.

Improving market conditions could be a boon for these big-time dividend stocks.

An aerospace giant and a pilot training/simulator company are great ways to play a recovery in commercial air traffic.

A biofuel producer and a solar component specialist are well-placed to benefit from a transition toward renewables.

I bought these stocks during “bad” times, but “good” times won’t get me to jettison them from my portfolio. They are just too reliable.

The electric vehicle start-up just upped its (Wall) street cred, but plenty of fundamental pitfalls lie ahead.